Evidence map›Paper›PMID 37862305›Full record

ArticlePloS one2023

Hunting for the elusive target antigen in gestational alloimmune liver disease (GALD).

Klaus Rieneck, Karen Koefoed Rasmussen, Erwin M Schoof, Frederik Banch Clausen, Henrietta Holze, Thomas Bergholt, Marianne Hørby Jørgensen, Vibeke Brix Christensen, Runar Almaas, Peter Lüttge Jordal and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Maternal Immunoglobulin Treatment of Gestational Alloimmune Liver Disease to Prevent Neonatal Liver Failure: A Single Center Case Series.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Article
  3. "Baby You're Just Not Right for Me": The Various Problems of Feto-Maternal Incompatibilities.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Klaus RieneckLaboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-7251-5754
Karen Koefoed RasmussenLaboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Erwin M SchoofDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark.ORCID 0000-0002-3117-7832
Frederik Banch ClausenLaboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Henrietta HolzeNovo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.ORCID 0000-0003-1589-3887
Thomas BergholtDepartment of Obstetrics and Gynecology, Herlev Hospital, Herlev, Copenhagen, Denmark.
Marianne Hørby JørgensenDepartment of Pediatric and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
Vibeke Brix ChristensenDepartment of Pediatric and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
Runar AlmaasDepartment of Pediatric Research, Oslo University Hospital, Oslo, Norway.
Peter Lüttge JordalSBT Instruments A/S, Herlev, Denmark.
Marie Locard-PauletNovo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.
Kasper RunagerTeknologisk Institut, Aarhus C, Denmark.
Leif Kofoed NielsenDepartment of Technology, Faculty of Health and Technology, University College Copenhagen, Copenhagen, Denmark.
Balthasar Clemens SchlotmannBiotech Research & Innovation Centre, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-8137-544X
Joachim Lütken WeischenfeldtBiotech Research & Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
Lars Juhl JensenNovo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.
Morten Hanefeld DziegielLaboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
Rigshospitalet · DKUniversity of Copenhagen · DKNovo Nordisk Foundation · DKDanish Technological Institute · DKOslo University Hospital · NOTechnical University of Denmark · DKUniversity College Copenhagen · DK

Funding

Medical Research Council MR/R006237/1
6 · The paper itself

Abstract

The prevailing concept is that gestational alloimmune liver disease (GALD) is caused by maternal antibodies targeting a currently unknown antigen on the liver of the fetus. This leads to deposition of complement on the fetal hepatocytes and death of the fetal hepatocytes and extensive liver injury. In many cases, the newborn dies. In subsequent pregnancies early treatment of the woman with intravenous immunoglobulin can be instituted, and the prognosis for the fetus will be excellent. Without treatment the prognosis can be severe. Crucial improvements of diagnosis require identification of the target antigen. For this identification, this work was based on two hypotheses: 1. The GALD antigen is exclusively expressed in the fetal liver during normal fetal life in all pregnancies; 2. The GALD antigen is an alloantigen expressed in the fetal liver with the woman being homozygous for the minor allele and the father being, most frequently, homozygous for the major allele. We used three different experimental approaches to identify the liver target antigen of maternal antibodies from women who had given birth to a baby with the clinical GALD diagnosis: 1. Immunoprecipitation of antigens from either a human liver cell line or human fetal livers by immunoprecipitation with maternal antibodies followed by mass spectrometry analysis of captured antigens; 2. Construction of a cDNA expression library from human fetal liver mRNA and screening about 1.3 million recombinants in Escherichia coli using antibodies from mothers of babies diagnosed with GALD; 3. Exome/genome sequencing of DNA from 26 presumably unrelated women who had previously given birth to a child with GALD with husband controls and supplementary HLA typing. In conclusion, using the three experimental approaches we did not identify the GALD target antigen and the exome/genome sequencing results did not support the hypothesis that the GALD antigen is an alloantigen, but the results do not yield basis for excluding that the antigen is exclusively expressed during fetal life., which is the hypothesis we favor.

Indexed as

Digestive System DiseasesFetal DiseasesHemochromatosisInfant, Newborn, DiseasesLiver DiseasesThrombocytopenia, Neonatal AlloimmuneChildFemaleHumansInfant, NewbornIsoantigensPregnancyIsoantigens

Identifiers

PMID37862305
PMCPMC10588877
OpenAlexW4387823304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.